21 completed, 5 unknown, 4 terminated, 3 recruiting. 13 Phase 3, 13 Phase 4, 12 Phase 2, 1 Early Phase 1, 1 Phase 1.
Follow Fluocinolone Acetonide: new trials by email Literature Review of Fluocinolone Acetonide trials Research Report on Fluocinolone Acetonide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Tranexamic Acid Plus Triple Combination vs Triple Combination Alone in Melasma Oral tranexamic acid + triple combination cream (fluocinolone acetonide + hydroquinone + tretinoin), Triple combination cream (fluocinolone acetonide + hydroquinone + tretinoin) alone - Melasma, Melasma (Facial Melasma) | Phase 4 | Not yet recruiting | Combined Military Hospital Abbottabad | 128 | 2026-07-15 | 2026-07-28 |
| Frequency and Intensity of Inflammatory Relapses in Patients With Non-infectious Posterior Uveitis Treated With a Fluocinolone Acetonide Implant fluocinolone acetonide intravitreal implant - Noninfectious Posterior Uveitis, Uveitis, Posterior | Not yet recruiting | Nantes University Hospital | 100 | 2026-06-01 | 2026-06-24 | |
| Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy Faricimab, fluocinolone acetonide - Radiation Retinopathy, Visual Impairment | Phase 3 | Recruiting | Jaeb Center for Health Research | 600 | 2023-11-21 | 2026-10-23 |
| A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis Yutiq - Uveitis, YUTIQ | Recruiting | Tianjin Medical University | 15 | 2023-01-05 | 2024-07-03 | |
| The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Yutiq 0.18 MG Drug Implant, Sham Injection - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Texas Retina Associates | 10 | 2022-10-05 | 2026-10-05 |
| Comparison Of Efficacy Of Combination Of TAM Formula Vs Kligman Formula For Melasma. TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C), Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%) - Melasma | Phase 2 | Unknown | Jinnah Postgraduate Medical Centre | 122 | 2022-08-01 | 2023-08-28 |
| Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis Fluocinolone Acetonide Intravitreal Implant 0.18 mg - Uveitis, Posterior | Phase 4 | Unknown | Alimera Sciences | 125 | 2022-06-06 | 2024-08-06 |
| Steroids for Early Treatment of Radiation Retinopathy Fluocinolone Acetonide (FA) implant - Radiation Retinopathy | Phase 2 / Phase 3 | Withdrawn | The Cleveland Clinic | 2022-02-01 | 2021-08-04 | |
| Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema Dexamethasone intravitreal implant, Fluocinolone Acetonide Intravitreal Implant - Diabetic Macular Edema | Phase 4 | Recruiting | Centre Hospitalier Universitaire Dijon | 106 | 2021-10-29 | 2025-05-09 |
| A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery Yutiq 0.18 MG Drug Implant - Glaucoma | Early Phase 1 | Active not recruiting | Sanjay Asrani | 5 | 2021-07-20 | 2025-11-10 |
| A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME) Iluvien 0.19 MG Drug Implant, Aflibercept - Diabetic Macular Edema | Phase 4 | Active not recruiting | Alimera Sciences | 300 | 2020-08-31 | 2024-07-31 |
| Combined Ranibizumab and Iluvien for Diabetic Macular Oedema Iluvien 0.19 MG Drug Implant, Ranibizumab Injection [Lucentis], Sham Intravitreal Injection - Diabetic Macular Edema, Diabetes | Phase 2 / Phase 3 | Withdrawn | Imperial College London | 2019-09-01 | 2023-10-02 | |
| Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant Fluocinolone Acetonide - Uveitis | Completed | The Cleveland Clinic | 30 | 2019-08-08 | 2026-02-05 | |
| Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant Retisert, Fluocinolone Acetonide Intravitreal Implant - Uveitis, Posterior | Completed | Bausch & Lomb Incorporated | 3 | 2017-07-14 | 2019-06-21 | |
| Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study ILUVIEN® - Diabetic Macular Edema | Phase 4 | Withdrawn | Johns Hopkins University | 2017-03-01 | 2017-08-22 | |
| Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates 0.19 mg fluocinolone acetonide (FAc) implant - Diabetic Macular Edema | Unknown | Benha University | 30 | 2017-01-13 | 2018-07-18 | |
| Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter - Non-Infectious Uveitis | Phase 3 | Completed | EyePoint Pharmaceuticals, Inc. | 26 | 2016-02-23 | 2020-05-01 |
| Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant Fluocinolone Acetonide 0.59 mg, Fluocinolone Acetonide 2.1 mg - Inflammation, Uveitis | Completed | Bausch & Lomb Incorporated | 98 | 2016-02-04 | 2019-06-21 | |
| Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis Sham Injection, FAI Insert - Posterior Uveitis, Intermediate Uveitis | Phase 3 | Completed | EyePoint Pharmaceuticals, Inc. | 153 | 2015-06-02 | 2020-07-21 |
| Phase 4 IOP Signals Associated With ILUVIEN® ILUVIEN 0.19 MG - Diabetic Macular Edema (DME) | Phase 4 | Completed | Alimera Sciences | 153 | 2015-05-06 | 2022-01-11 |
Showing 20 of 40. Sign in to see all of them.
Uveitis (7) · Uveitis, Posterior (6) · Melanosis (5) · Macular Degeneration (3) · Macular Edema (3) · Uveitis, Intermediate (2) · Behcet Syndrome (1) · Diabetes Mellitus (1) · Diabetic Retinopathy (1) · Geographic Atrophy (1) · Glaucoma (1) · Inflammation (1) · Panuveitis (1) · Retinal Vein Occlusion (1) · Uveitis, Anterior (1)
Alimera Sciences (9) · Bausch & Lomb Incorporated (7) · Galderma R&D (3) · EyePoint Pharmaceuticals, Inc. (2) · Johns Hopkins University (2) · The Cleveland Clinic (2) · Asan Medical Center (1) · Association for Innovation and Biomedical Research on Light and Image (1) · Benha University (1) · Centre Hospitalier Universitaire Dijon (1) · Combined Military Hospital Abbottabad (1) · Control Delivery Systems (1) · Duke University (1) · Glenn Jaffe (1) · Imperial College London (1)
United States (25) · China (2) · France (2) · India (2) · Pakistan (1) · Portugal (1) · South Korea (1) · United Arab Emirates (1)
Flavio Leonin Jr., MD (2) · Ronald W Gottschalk, MD (2) · Ali Amar, MBBS, FCPS, CHPE (1) · Antonio Cutino (1) · Carlos Pavesio, MD (1) · Dennis Lam Shun-Chiu, MD (1) · Gerard E Riedel, PhD (1) · Glenn J Jaffe, MD (1) · Glenn J. Jaffe, MD (1) · Gulnar Hafiz, MD, MPH (1) · Johnson Varughese (1) · Laura Trusso (1) · Paul Ashton, PhD (1) · Peter A Campochiaro, MD (1) · Richard Cheong-Leen (1)
PMID 16690128, PMID 18779477, PMID 20079922, PMID 20398959, PMID 30569759, PMID 32461262, PMID 33206392, PMID 38027419, PMID 38189802, PMID 41887289
UG1EY014231 (1)